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Abstract
The majority of causative variants in familial breast cancer remain unknown. Of the known risk variants, most are tumor cell autonomous and little attention has been paid yet to germline variants that may affect the tumor microenvironment. In this study, we developed a system called the Consomic Xenograft Model (CXM) to map germline variants that impact only the tumor microenvironment. In CXM, human breast cancer cells are orthotopically implanted into immunodeficient consomic strains and tumor metrics are quantified (e.g., growth, vasculogenesis, and metastasis). Because the strain backgrounds vary, whereas the malignant tumor cells do not, any observed changes in tumor progression are due to genetic differences in the non-malignant microenvironment. Using CXM, we defined genetic variant(s) on rat chromosome 3 that reduced relative tumor growth and hematogenous metastasis in the SS.BN3
IL2RȖ consomic model compared to the SS IL2RȖ parental strain. Paradoxically, these effects occurred despite an increase in the density of tumor-associated blood vessels. In contrast, lymphatic vasculature and lymphogenous metastasis were unaffected by the SS.BN3 IL2RȖ background. Through comparative mapping and whole genome sequence analysis, we narrowed candidate variants on rat chromosome 3 to six genes with a priority for future analysis.
Collectively, our results establish the utility of CXM to localize genetic variants affecting the tumor microenvironment which underlie differences in breast cancer risk.
Introduction
Breast cancer is the most prevalent female malignancy (http://apps.nccd.cdc.gov/uscs/) and is highly heritable (1) (2) (3) (4) , yet ~72% of breast cancer risk remains undefined (5) . Heritable factors underlie most aspects of breast cancer risk [e.g., incidence (5), age-of-onset (6), metastatic progression (7), and disease-free survival (8) ]. In addition to variants that impact tumor cells directly (i.e., tumorigenicity), heritability is implicated in multiple components of the tumor microenvironment [e.g., tissue remodeling (9), angiogenesis (10, 11) , and immunity (12) ], which also impact tumorigenesis and progression. However, the genetic variant(s) underlying differences in the tumor microenvironment have rarely been the focus of genetic mapping studies and as such, remain poorly defined.
We have developed a new model of breast cancer (termed the Consomic Xenograft
Model -CXM) that focuses on genetic mapping of strain-specific variant(s) that impact tumor progression through the tumor microenvironment. A consomic rat is one in which an entire chromosome is introgressed into the isogenic background of another inbred strain by selective breeding (13) . Thus, observed phenotypes can be linked to single chromosomes and then further elucidated by comparative sequence analysis and/or selective backcrossing to yield smaller congenics (13) . In CXM, the consomic and parental strains are converted to SCID (severe combined immunodeficiency), so that orthotopically xenografted human breast cancer cells can be tested in vivo. Because the human breast cancer cells are not varied between strains, any differences in breast cancer progression (e.g., primary site growth, vasculogenesis, and distal metastasis) are due solely to genetic differences in the tumor microenvironment, not the malignant cancer cells. CXM utilizes transgenically tagged human cancer cells with defined
properties (e.g., triple-negative, pro-metastatic, etc.). Thus, it enables testing of clinically 5 relevant cancer models in strain backgrounds with varying genetic predispositions to breast cancer. Finally, we have developed CXM in the rat, but postulate that this technique could also be applied to the mouse and other model species.
For purposes of illustration, the basic concept of CXM is outlined in Figure 1 . In brief, CXM utilizes TALENs (14) to generate SCID on any strain background by mutating the IL2RȖ gene (15) . We first generated and characterized an IL2RȖ mutant parental SS strain (SS IL2RȖ ), which was then selectively bred onto the SS.BN3 consomic background to generate the SS.BN3 IL2RȖ consomic. The parental SS (SS/JrHsdMcwi) rat strain is susceptible to mammary tumors, whereas the BN (BN/NHsdMcwi) rat strain is highly resistant to mammary tumors (16).
Our rationale for choosing SS (parental) and SS.BN3 consomic (i.e., BN chromosome 3 introgressed onto the isogenic SS background) was based on prior data demonstrating a 64% reduction in breast cancer incidence in the SS.BN3 consomic compared with the SS (16) and other evidence that multiple overlapping protective loci exist on rat chromosome 3 (16) (17) (18) (19) generation.
Tumor Implantation
Luciferase-tagged MDA-MB-231 (231 Luc+ ) cells were orthotopically implanted and measured as described previously (21), with slight modifications. Briefly, 231 Luc+ cells (6 × 10 6 ) in 50%
Matrigel were mammary fat pad (MFP) of 4-to 6-week-old female SS IL2Rg (n = 11) and SS.BN3 IL2Rg (n = 19) rats. Tumor volumes were measured weekly by calipers, as described previously (21) .
Detection of Lung Metastasis by Ex Vivo Luminescent Imaging
Rats were intraperitoneally injected with 200 μl of d-luciferin (Promega, Madison, WI) diluted in sterile saline (40 mg/ml). The substrate was allowed to circulate for 5 minutes before rats were euthanized and lunges were removed for bioluminescence imaging using the Xenogen Ivis Lumina (Caliper Life Sciences, Hopkinton, MA).
Detection of Metastatic Burden by Luciferase Activity
Ipsilateral axillary lymph nodes and lungs were excised, washed in PBS, and homogenized in 0. 
Histological Detection of Lung Metastasis
Metastatic lesions in the lungs of tumor-bearing SS IL2RȖ (n = 5) and SS.BN3 IL2RȖ (n =5) rats were also assessed by hematoxylin and eosinophil (H&E) staining, as described previously (22) .
Formalin fixed lung sections were H&E-stained using a Tissue-Tek Prisma Automated Stainer (Sakura, Torrance, CA) according to the manufacturer's protocol. Following H&E staining, three serial sections per lung were examined by two blinded observers.
Matrigel Plug Angiogenesis Assay
Female SS (n = 9) and SS.BN3 (n = 19) rats at 6-8 weeks-of-age were implanted in the MFP with 500 μl of 100% matrigel (cat. CB-40234; BD Biosciences, San Jose, CA) supplemented with 500ng/ml of recombinant rat VEGFA 164 purchased (R&D Systems, Minneapolis, MN). At 5 days-post implantation, matrigel plugs were excised, snap-frozen in OCT (Tissue Tek, Torrance, CA) and stained with anti-CD31 as described in the Expanded Materials and Methods.
Blood and Lymphatic Vessel Densities
231
Luc+ tumors and matrigel plugs were excised, frozen-sectioned, and immunostained with antibodies against the blood vessel marker, CD31, or the lymphatic vessel marker, LYVE-1, as described previously (23 
Quantification of Blood Vessel Densities (BVD) in DMBA-induced Mammary Tumors
Acquisition of DMBA-induced mammary tumors from the SS.BN3 consomic (n = 9) and SS (n = 9) rats were previously described by Adamovic et al (16) . These tumors were previously formalin fixed and paraffin embedded, precluding us from using the traditional anti-CD31 antibody that does not recognize formalin-fixed antigens. To circumvent this issue, DMBA- 
Peripheral Blood Analysis
Whole blood from anesthetized rats was analyzed by automated complete blood counts (Marshfield Laboratories, Waukesha, WI) and flow cytometry was performed, as described previously (24, 25). 
Genomic Sequencing and Analysis
Genomic sequence was accessed from the Rat Genome Database (http://rgd.mcw.edu/) and has been described in detail elsewhere (26-28).
Statistical analysis
Statistical analyses were performed using Sigma Plot 11.0 software. Data are presented as mean ± SEM. All data were analyzed by unpaired Student t test. 
Results
Consomic Xenograft Model (CXM)
Traditional mapping studies localize cancer risk variants (29), but do not differentiate between variants that impact malignant cells directly versus those that affect the tumor microenvironment.
Here, our goal was to develop a new genetic model of breast cancer risk (i.e., CXM), whereby genetic variants that specifically impact breast cancer progression through the tumor microenvironment are mapped. 
Tumor Growth
Previously we showed that the SS.BN3 consomic rat has significantly reduced tumorigenicity in a DMBA-inducible model of breast cancer (16) . We postulated that this could be at least partially due to genetic differences in the tumor microenvironment, rather than inherent differences in the 
Tumor Angiogenesis and Hematogenous Metastasis
To assess blood vessel density (BVD), 231 Luc+ tumors that were orthotopically implanted in
MFPs of SS IL2RȖ (n = 5 rats) and SS.BN3 IL2RȖ (n = 6 rats) rats were excised at 24 days postimplantation and stained with antibodies against the blood vessel marker, CD31 (23, 31) ( Figure   3A Figure 3B ) is present in the unmodified parental SS and SS.BN3 consomic strains using two independent methods: a matrigel plug angiogenesis assay (34) and reanalysis of the DMBA-inducible mammary tumors from Adamovic et al (16) . For the matrigel plug angiogenesis assay, female SS and SS.BN3 consomic rats were implanted with 500 μl of matrigel supplemented with 500 ng/ml of recombinant rat VEGF 164 . At 5 days post-implantation, matrigel plugs were excised and quantified for CD31 + blood vessels across the entire crosssection of the plug. Compared with SS plugs (14 ± 3 vessels/mm 2 ; n = 9 rats), the BVD in SS.BN3 consomic rats was ~2-fold higher (23 ± 4 vessels/mm 2 ; P < 0.05; n = 19 rats) ( Figure   4A , B). Likewise, BVD of SS.BN3 mammary tumors (n = 9) from the DMBA-inducible model showed a ~2-fold (P < 0.01) increase relative to SS tumors (n = 9) from the same study (16) ( Figure 4C, D) , collectively demonstrating that SS.BN3 has increased angiogenic potential (i.e., the ability to form new blood vessels), despite having decreased tumor growth, vascular invasion, and hematogenous metastasis (Figures 2 and 3 ).
Tumor Lymphangiogenesis and Lymphogenous Metastasis
To 
Our data demonstrate that genetic element(s) on BN chromosome 3 affect tumor growth, vascularity, vascular invasion, and metastasis (Figures 2-5 ). Overlapping cancer QTLs on rat chromosome 3 were previously reported in independent F 2 crosses using cancer resistant 
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6A-C), indicating that the genetic mechanism(s) underlying these similar QTLs are likely shared in these regions. Combined, these data suggest that common heritable elements are most likely enriched in the overlapping cancer QTLs (16) (17) (18) (19) .
Using the cosegregating variant analysis we preliminarily reduced the list of candidate variants from 455,272 total variants on rat chromosome 3 to 15,031 variants (3.3% of total chromosome 3 variants) in the cosegregating region (chr3:50.5-88.0Mb) that overlapped with the three cancer QTLs (17) (18) (19) . Of the 15,031 cosegregating variants, 46 lie within coding regions of conserved genes, 10 are expected to cause nonsynonymous amino acid changes, and 2 of these were predicted to be damaging by Provean (http://provean.jcvi.org/seq_submit.php; Table 1 and   Supplementary Table 3 ).
Comparative Genomics
Our data suggest that cosegregating genetic element(s) on rat chromosome 3 affect tumor growth, angiogenesis, vascular invasion, and metastasis (Figures 2-5A ). The 37.5 Mb region Table 2 ) and is syntenic to two regions on human chromosomes 2 and 11 ( Figure 6D ) and one region on mouse chromosome 2 (data not show). A total of four genes [METAP1D (5), CDCA7 (5), PTPRJ (36), and CD44 (37-40)] in syntenic regions of the human genome have been associated with breast cancer risk ( Figure 6D ), whereas no mouse studies have reported associations for breast cancer in the syntenic mouse region. Of the human risk genes, METAP1D and CDCA7 were associated with breast cancer incidence by genome wide association study (GWAS) (5) . CD44 has been associated with multiple aspects of human breast cancer risk: incidence (39), age-of-onset (37, 40), angiogenesis (41), metastasis (42) , and survival (39, 43, 44 
Discussion
The heritability of breast cancer is well established (1-3 ), yet the majority of causative variants remain unknown (5) . Of the few known variants, most are considered tumor cell-autonomous (47) (48) (49) , with far less emphasis placed on germline variants that might impact breast cancer progression through the tumor microenvironment. We developed an experimental model that specifically focused on mapping genetic variant(s) underlying differences in the tumor microenvironment. CXM utilizes genetically "fixed" tumor cells that are xenografted into rat strains with different genetic backgrounds, so that any observed differences in tumor progression (e.g., growth, vasculogenesis, and metastasis) would be attributable to the tumor microenvironment, including interaction between the tumor and host. From a clinical perspective, these data show that germline variants in the tumor microenvironment impact breast cancer risk and should be taken into account in future studies. As a technical advancement, this work demonstrates that CXM can be used to directly map germline variants in the tumor microenvironment for the first time.
Using CXM, we demonstrated that genetic variant(s) on BN chromosome 3 inhibited tumor growth and lung metastasis of 231
Luc+ breast cancer cells (Figures 2 and 3 ), without affecting LN metastasis ( Figure 5 ). Sequence analysis by cross-strain comparisons and comparative analysis prioritized a list of 6 candidate genes for future study ( Figure 6 and Table   1 (20, 52, 53) , all of which we have done previously for other disease loci (see below for description).
Breast Cancer Risk QTL on Rat Chromosome 3
Previously, we (16) syndrome patients with trisomy 21, due to increased gene-dosage of DSCR1 (55) . The important distinction is that Down's syndrome is a non-mendelian genetic disease, whereas our findings suggest that common germline variant(s) could have similar effects in a much broader spectrum of patients. Our data also suggest that "looks can be deceiving" -i.e., metastatic potential and tumor growth are frequently correlated with vascular density (33), but based on our findings this might not always be the case. Instead, we propose that variants affecting vascular function and maturity will similarly impact breast cancer progression, which might be overlooked as a prognostic indicator by relying on vascular density only. Finally, from a translational viewpoint, the findings of this study indicate that some germline variant(s) could potentially function as "genetic switches" between hematogenous and lymphogenous metastasis. Thus, a better understanding of germline variant(s) that impact tumor metastasis will likely yield better patient stratification for vascular-specific adjuvant therapies [e.g., bevacizumab (56), TKi (57), etc.].
Using CXM and Similar Strategies to Localize Cancer Risk Variants
From a technical standpoint, we posit that CXM can be tailored to further elucidate causative variants using additional mapping strategies (e.g., F 2 intercross, congenic, gene-editing, etc.) or to test interactions with other clinically relevant subsets of breast cancer (e.g., luminal, lobular, inflammatory, etc.). Our rationale for first using a consomic was (1) to develop the general technique and (2) to localize the phenotype to a specific chromosome before proceeding further.
Using CXM and comparative mapping, we narrowed the list of potential candidate variants in the rat chromosome 3 QTL by 96.7%. Now, it would be foreseeable to physically narrow the QTL(s), with the ultimate goal of localizing the causative variant(s). Because TALENs and ZFNs do not require specific rat strains (we have now gene-edited on >10 backgrounds; http://rgd.mcw.edu/wg/physgenknockouts), it would be possible to generate SCID rats (or mice) background, an approach that we have used previously for other disease loci (53) . Finally, although we developed CXM for the rat, we have also demonstrated the utility of TALEN-or ZFN-mediated gene-editing in the mouse (58) and therefore, CXM could be used in mice and potentially other model organisms.
Experimental Considerations of the CXM Strategy
There are several limitations of cancer xenograft models that should be considered when interpreting CXM data. Firstly, like all xenograft models, CXM utilizes SCID rodents that lack fully intact immune systems and thus genetic variants that impact tumor immunity might not be accessible. Secondly, xenotransplantation of human cancer cells into rodent backgrounds might not recapitulate species-specific mechanisms, but rather only mechanisms conserved across species. Finally, some germline variants likely affect both malignant tumor cells and the nonmalignant stromal cells, whereas CXM would only detect effects on the nonmalignant stroma. Despite these limitations, there are also considerable advantages of CXM, including the ability to use etiologically defined and clinically relevant human cell lines that are transgenically-tagged for better tracking in vivo.
Perspective
CXM is the first model for mapping germline variants in the tumor microenvironment. To do so, CXM combines genome-editing (via TALENs), a genetic mapping tool (the consomic), and a widely used model of human breast cancer (the tumor xenograft). As proof-of-concept, we 
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demonstrated that CXM can detect germline variant(s) in an established breast cancer QTL (17) (18) (19) (Figures 2 and 3) . Using CXM, we also demonstrated that the causative variant(s) on rat chromosome 3 affected the tumor blood vasculature, which potentially disrupted tumor growth and metastasis. Follow-up studies using cell culture systems, localization of candidate gene expression and tissue-specific gene-editing will be required to determine whether the causative variant(s) function directly or indirectly through the blood vasculature. In summary, CXM is a technical advance that localizes cancer phenotypes to a single chromosome and could be used to isolate causative variants/genes by congenic mapping and/or candidate gene-targeting. 
